Zofran: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) (expand) |
Notjusttired (talk | contribs) m (Text replacement - "|title=" to " | title = ") |
||
| (16 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{stub}} | {{stub}} | ||
'''Zofran''' or '''ondansetron''' (generic name, oral) is drug used to treat [[nausea]] and vomiting.<ref name="drugscom">{{Cite web|url=https://www.drugs.com/zofran.html|title=Zofran Uses, Dosage & Side Effects|website=Drugs.com|language=en|access-date=2020-11-29}}</ref> Zofran is also sold under the brand names Zofran ODT and Zuplenz.<ref name="drugscom" /> | '''Zofran''' or '''ondansetron''' (generic name, oral) is drug used to treat [[nausea]] and vomiting.<ref name="drugscom">{{Cite web|url=https://www.drugs.com/zofran.html | title = Zofran Uses, Dosage & Side Effects|website=Drugs.com|language=en|access-date=2020-11-29}}</ref> It is a 5-HT3 receptor antagonist.<ref name=":0">{{Cite journal | last =Späth| first = M.|author-link = | last2 = Färber, D. | first2 = L.|author-link2 = | last3 = Welzel | first3 = D. | authorlink3 = | date = 2000-01-01 | title = Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results|url=https://doi.org/10.1080/030097400750001851-1|journal=Scandinavian Journal of Rheumatology|volume=29|issue=113|pages=72–77|doi=10.1080/030097400750001851-1|issn=0300-9742|pmc=|pmid=|access-date=|quote=|via=}}</ref> Zofran is also sold under the brand names Zofran ODT and Zuplenz.<ref name="drugscom" /> | ||
==Theory== | |||
==Evidence== | |||
==Clinicians== | |||
==Risks and safety== | |||
Serious side effects may occur with zofran including: | Serious side effects may occur with zofran including: | ||
* blurred vision or vision loss (lasting from a few minutes to several hours) | * blurred vision or vision loss (lasting from a few minutes to several hours) | ||
| Line 12: | Line 19: | ||
* Urinating less than usual or not urinating at all | * Urinating less than usual or not urinating at all | ||
Zofran may impair your thinking or reactions, which may make driving unsafe.<ref name="drugscom" /> | Zofran may impair your thinking or reactions, which may make driving unsafe.<ref name="drugscom" /> | ||
==Costs and availability== | |||
== Notable studies == | |||
* 2009, Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results<ref name=":0" /> [https://doi.org/10.1080/030097400750001851-1 (Abstract)] | |||
== See also == | == See also == | ||
| Line 20: | Line 32: | ||
== References == | == References == | ||
{{Reflist}} | |||
[[Category:Potential treatments]] | [[Category:Potential treatments]] | ||
[[Category:Antiemetics]] | |||
Latest revision as of 20:21, April 2, 2023
 | This article is a stub. |
Zofran or ondansetron (generic name, oral) is drug used to treat nausea and vomiting.[1] It is a 5-HT3 receptor antagonist.[2] Zofran is also sold under the brand names Zofran ODT and Zuplenz.[1]
Theory[edit | edit source]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Serious side effects may occur with zofran including:
- blurred vision or vision loss (lasting from a few minutes to several hours)
- Slowed heart rate
- Difficultty breathing
- Anxiety
- Agitation
- Shivering
- feeling like you might pass out
- Urinating less than usual or not urinating at all
Zofran may impair your thinking or reactions, which may make driving unsafe.[1]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2009, Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results[2] (Abstract)
See also[edit | edit source]
Learn more[edit | edit source]
- Zofran - drugs.com
References[edit | edit source]
- ↑ 1.0 1.1 1.2 "Zofran Uses, Dosage & Side Effects". Drugs.com. Retrieved November 29, 2020.
- ↑ 2.0 2.1 Späth, M.; Färber, D., L.; Welzel, D. (January 1, 2000). "Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results". Scandinavian Journal of Rheumatology. 29 (113): 72–77. doi:10.1080/030097400750001851-1. ISSN 0300-9742.
